Table 2: Clinical trials of rectal cancer [78].
Study |
Key inclusion criteria |
Treatment |
Outcomes |
Ngan, et al. [71] |
T3,T4 |
RT short course and immediate surgery RT long course and delayed surgery |
DFS: 67% vs. 66% Recurrence: 9% vs. 14.2% |
Van Djk, et al. [79] |
Stage IV |
RT short course + CAPOX + Bebazizumab |
pCR: 26% |
Tunio, et al. [80] |
T4 |
RQnt QT with capecitabineT
+ neoadyuv |
pCR: 85.4% |
Bujko, et al. [70] |
Stage IV |
NUeoadyuvant RT short course + FOLFOX
vs. QRT with 5-F |
pCR: 21% vs. 9% |
Garcia-Aguilera |
T3,T4 |
RT with 5 FU RT with 5 FU followed by FOLFOX x 4 weeks |
pCR: 18% vs. 25% |
DFS:
Disease Free Survival, pCR: Pathologic Complete
Response